MX2024002150A - Anticuerpos y proteinas de fusion de igg con una semivida prolongada. - Google Patents

Anticuerpos y proteinas de fusion de igg con una semivida prolongada.

Info

Publication number
MX2024002150A
MX2024002150A MX2024002150A MX2024002150A MX2024002150A MX 2024002150 A MX2024002150 A MX 2024002150A MX 2024002150 A MX2024002150 A MX 2024002150A MX 2024002150 A MX2024002150 A MX 2024002150A MX 2024002150 A MX2024002150 A MX 2024002150A
Authority
MX
Mexico
Prior art keywords
fusion proteins
antibodies
life
region
igg
Prior art date
Application number
MX2024002150A
Other languages
English (en)
Spanish (es)
Inventor
Mohamad Morsey
Seth D Stauffer
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2024002150A publication Critical patent/MX2024002150A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024002150A 2021-08-20 2022-08-19 Anticuerpos y proteinas de fusion de igg con una semivida prolongada. MX2024002150A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163235261P 2021-08-20 2021-08-20
US202163235259P 2021-08-20 2021-08-20
US202263341443P 2022-05-13 2022-05-13
PCT/EP2022/073145 WO2023021169A1 (en) 2021-08-20 2022-08-19 Antibodies and igg fusion proteins with an extended half-life

Publications (1)

Publication Number Publication Date
MX2024002150A true MX2024002150A (es) 2024-03-08

Family

ID=83280226

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002150A MX2024002150A (es) 2021-08-20 2022-08-19 Anticuerpos y proteinas de fusion de igg con una semivida prolongada.

Country Status (7)

Country Link
US (1) US20250197514A1 (https=)
EP (1) EP4388004A1 (https=)
JP (1) JP2024531346A (https=)
AU (1) AU2022329459A1 (https=)
CA (1) CA3227716A1 (https=)
MX (1) MX2024002150A (https=)
WO (1) WO2023021169A1 (https=)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP6701079B2 (ja) 2013-12-20 2020-05-27 インターベット インターナショナル ベー． フェー． ヒトｐｄ−１に対するイヌ化マウス抗体
WO2018073185A1 (en) 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
JP7399880B2 (ja) 2018-01-26 2023-12-18 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
CN113194984A (zh) 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
US11542333B2 (en) * 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US20220169740A1 (en) 2019-03-20 2022-06-02 Kindred Biosciences, Inc. NGF Antagonists for Medical Use
FR3104217B1 (fr) 2019-12-10 2021-12-24 Innov Shoes Dispositif d’assemblage amovible entre deux pièces
MX2022007636A (es) * 2019-12-20 2022-07-19 Intervet Int Bv Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
US11434276B2 (en) 2020-05-11 2022-09-06 Invetx, Inc. Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use

Also Published As

Publication number Publication date
JP2024531346A (ja) 2024-08-29
EP4388004A1 (en) 2024-06-26
CA3227716A1 (en) 2023-02-23
AU2022329459A1 (en) 2024-02-29
US20250197514A1 (en) 2025-06-19
WO2023021169A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
Kraft et al. Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis
US12158473B2 (en) Multimeric protein purity determination
UA86605C2 (ru) Антитело, которое содержит вариант исходного человеческого fс-участка
MX2020001707A (es) Variantes igg fc para uso veterinario.
EA201100527A1 (ru) Биологические продукты
CY1116863T1 (el) Πρωτεϊνη δεσμευσης υποδοχεα nogo
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
CY1118462T1 (el) Μονοκλωνικο αντισωμα κατα της πρωτεϊνης συνδεσης οστεοπροτεγερινης
EA201171259A1 (ru) Антительные гибридные белки с модифицированными сайтами связывания fcrn
BRPI0507433C1 (pt) anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
EA200700751A1 (ru) Способы и композиции для улучшения продуцирования рекомбинантного белка
MA34527B1 (fr) Anticorps contre la metalloproteinase de matrice 9
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
Matte Approaches to the purification, analysis and characterization of antibody-based therapeutics
JP2016531546A5 (https=)
WO2021236983A3 (en) Methods and compositions for protein sequencing
SA522440646B1 (ar) أجسام مضادة ترتبط بـ siglec15 واستخداماتها
PE20230348A1 (es) Variantes de anticuerpos felinos
EA202092458A1 (ru) Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
CO2025012426A2 (es) Polipéptidos que se unen al receptor de fc neonatal
KR20220012263A (ko) 항체의 도메인-특이적 전하 변이체의 특징규명
MX2024002150A (es) Anticuerpos y proteinas de fusion de igg con una semivida prolongada.
EP4222162A4 (en) RECOMBINANT FUSION PROTEINS COMPRISING AN INTERLEUKIN-18 BINDING PROTEIN AND A SERUM ALBUMIN ANTIGEN BINDING FRAGMENT, COMPOSITIONS AND USES THEREOF
MX2023009549A (es) Compuestos y metodos para prolongar la vida media de biomoleculas.